A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence

FemmePharma Global Healthcare, Inc.45 enrolled

Overview

The purpose of this study is to determine the safety of three doses of oxybutynin for the treatment of urge urinary incontinence.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Urinary Incontinence, Urge

Interventions

oxybutyninDRUG

low dose oxybutynin administered daily

oxybutyninDRUG

middle dose oxybutynin administered daily

oxybutyninDRUG

high dose oxybutynin administered daily

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Females 18 to 75 years of age * Has reported symptoms of urge urinary incontinence/overactive bladder Exclusion Criteria: * Is pregnant or lactating * Has had lower urinary tract surgery within 6 months prior to Screening * Has a history of urinary retention

Locations (2)

SNBL Clinical Pharmacology Center

Baltimore, Maryland, United States

Advanced Biomedical Research

Hackensack, New Jersey, United States

Outcomes

Primary Outcomes

Number of micturations and incontinence episodes.

Time frame: Two weeks pretreatment and three weeks on treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.